Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer

The role and therapeutic promise of poly-ADP ribose polymerase (PARP) inhibitors in anticancer chemotherapy are increasingly being explored, particularly in adjuvant or maintenance therapy, considering their low efficacy as monotherapy agents and their potentiating effects on concurrently administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Shiue-Wei, Bamodu, Oluwaseun Adebayo, Chen, Jia-Hong, Wu, Alexander TH, Lee, Wei-Hwa, Chao, Tsu-Yi, Yeh, Chi-Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226837/
https://www.ncbi.nlm.nih.gov/pubmed/32276472
http://dx.doi.org/10.3390/cells9040911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226837/
https://www.ncbi.nlm.nih.gov/pubmed/32276472
http://dx.doi.org/10.3390/cells9040911

Ejemplares similares